Single User License
INR 135860
Site License
INR 271720
Corporate User License
INR 407580

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline Review, H1 2015

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline Review, H1 2015', provides an overview of the Reflux Esophagitis (Gastroesophageal Reflux Disease)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Reflux Esophagitis (Gastroesophageal Reflux Disease)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Reflux Esophagitis (Gastroesophageal Reflux Disease) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Reflux Esophagitis (Gastroesophageal Reflux Disease) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Reflux Esophagitis (Gastroesophageal Reflux Disease)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Reflux Esophagitis (Gastroesophageal Reflux Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Reflux Esophagitis (Gastroesophageal Reflux Disease) Overview 8

Therapeutics Development 9

Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease)-Overview 9

Pipeline Products for Reflux Esophagitis (Gastroesophageal Reflux Disease)-Comparative Analysis 10

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Therapeutics under Development by Companies 11

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Therapeutics under Investigation by Universities/Institutes 13

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline Products Glance 14

Late Stage Products 14

Clinical Stage Products 15

Early Stage Products 16

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Products under Development by Companies 17

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Products under Investigation by Universities/Institutes 19

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Companies Involved in Therapeutics Development 20

Ahn-Gook Pharmaceutical Co., Ltd. 20

aRigen Pharmaceuticals, Inc. 21

Cempra, Inc. 22

Daewoong Pharmaceutical Co., Ltd. 23

Eisai Co., Ltd. 24

Ironwood Pharmaceuticals, Inc. 25

Johnson & Johnson 26

Ono Pharmaceutical Co., Ltd. 27

RaQualia Pharma Inc. 28

Rottapharm SpA 29

Shire Plc 30

Sucampo Pharmaceuticals, Inc. 31

Vecta Ltd. 32

Wockhardt Limited 33

Yuhan Corporation 34

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Therapeutics Assessment 35

Assessment by Monotherapy Products 35

Assessment by Target 36

Assessment by Mechanism of Action 38

Assessment by Route of Administration 40

Assessment by Molecule Type 42

Drug Profiles 44

ARH-1029-Drug Profile 44

Product Description 44

Mechanism of Action 44

R&D Progress 44

cobiprostone-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

DWJ-1367-Drug Profile 47

Product Description 47

Mechanism of Action 47

R&D Progress 47

E-3710-Drug Profile 48

Product Description 48

Mechanism of Action 48

R&D Progress 48

esomeprazole magnesium-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

itriglumide-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

IW-3718-Drug Profile 51

Product Description 51

Mechanism of Action 51

R&D Progress 51

JNJ-26070109-Drug Profile 52

Product Description 52

Mechanism of Action 52

R&D Progress 52

omeprazole-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

ONO-8539-Drug Profile 55

Product Description 55

Mechanism of Action 55

R&D Progress 55

pantoprazole-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

RQ-00000004-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

RQ-00000010-Drug Profile 58

Product Description 58

Mechanism of Action 58

R&D Progress 58

RQ-00000774-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

Small Molecules to Agonize Motilin Receptor for GERD and Diabetic Gastroparesis-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

Small Molecules to Inhibit Proton Pump for Gastrointestinal Disorders-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

SSP-002358-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

tenatoprazole-Drug Profile 63

Product Description 63

Mechanism of Action 63

R&D Progress 63

Vaccine to Target Gastrin for Gastrointestinal Cancers-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

YH-4808-Drug Profile 66

Product Description 66

Mechanism of Action 66

R&D Progress 66

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Recent Pipeline Updates 67

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Dormant Projects 71

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Discontinued Products 74

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Product Development Milestones 77

Featured News & Press Releases 77

Mar 18, 2014: Ironwood Pharmaceuticals Initiates Phase II Clinical Study of IW-3718 in Refractory Gastroesophageal Reflux Disease 77

Sep 04, 2012: Santarus Announces Appellate Court Reversal In Part Of Zegerid Invalidity Decision 77

Mar 29, 2011: RaQualia Pharma Announces Successful Results From Phase I Study Of Acid Pump Antagonist 78

Apr 01, 2010: Santarus Announces Launch of ZEGERID OTC by Schering-Plough Consumer HealthCare 78

Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck 79

Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations 80

Dec 22, 2009: Santarus Receives Previously Announced $20 Million Milestone for FDA Approval of ZEGERID OTC 80

Dec 05, 2009: Santarus Receives FDA Approval for Immediate-Release Omeprazole 81

Dec 01, 2009: Santarus Announces FDA Approval of Schering-Plough HealthCare Products' ZEGERID OTC 81

Oct 26, 2009: Santarus To Present Positive Data From Two Investigator-Initiated Studies With ZEGERID At ACG 2009 Meeting 82

Appendix 83

Methodology 83

Coverage 83

Secondary Research 83

Primary Research 83

Expert Panel Validation 83

Contact Us 83

Disclaimer 84

List of Tables

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2015 9

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 12

Number of Products under Investigation by Universities/Institutes, H1 2015 13

Comparative Analysis by Late Stage Development, H1 2015 14

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Development, H1 2015 16

Products under Development by Companies, H1 2015 17

Products under Development by Companies, H1 2015 (Contd..1) 18

Products under Investigation by Universities/Institutes, H1 2015 19

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Ahn-Gook Pharmaceutical Co., Ltd., H1 2015 20

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by aRigen Pharmaceuticals, Inc., H1 2015 21

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Cempra, Inc., H1 2015 22

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Daewoong Pharmaceutical Co., Ltd., H1 2015 23

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Eisai Co., Ltd., H1 2015 24

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Ironwood Pharmaceuticals, Inc., H1 2015 25

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Johnson & Johnson, H1 2015 26

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 27

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by RaQualia Pharma Inc., H1 2015 28

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Rottapharm SpA, H1 2015 29

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Shire Plc, H1 2015 30

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Sucampo Pharmaceuticals, Inc., H1 2015 31

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Vecta Ltd., H1 2015 32

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Wockhardt Limited, H1 2015 33

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Pipeline by Yuhan Corporation, H1 2015 34

Assessment by Monotherapy Products, H1 2015 35

Number of Products by Stage and Target, H1 2015 37

Number of Products by Stage and Mechanism of Action, H1 2015 39

Number of Products by Stage and Route of Administration, H1 2015 41

Number of Products by Stage and Molecule Type, H1 2015 43

Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics-Recent Pipeline Updates, H1 2015 67

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Dormant Projects, H1 2015 71

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Dormant Projects (Contd..1), H1 2015 72

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Dormant Projects (Contd..2), H1 2015 73

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Discontinued Products, H1 2015 74

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Discontinued Products (Contd..1), H1 2015 75

Reflux Esophagitis (Gastroesophageal Reflux Disease)-Discontinued Products (Contd..2), H1 2015 76

List of Figures

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease), H1 2015 9

Number of Products under Development for Reflux Esophagitis (Gastroesophageal Reflux Disease)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Clinical Stage Development, H1 2015 15

Comparative Analysis by Early Stage Products, H1 2015 16

Assessment by Monotherapy Products, H1 2015 35

Number of Products by Top 10 Targets, H1 2015 36

Number of Products by Stage and Top 10 Targets, H1 2015 36

Number of Products by Top 10 Mechanism of Actions, H1 2015 38

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 38

Number of Products by Top 10 Routes of Administration, H1 2015 40

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 40

Number of Products by Top 10 Molecule Types, H1 2015 42

Number of Products by Stage and Top 10 Molecule Types, H1 2015 42

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Ahn-Gook Pharmaceutical Co., Ltd.

aRigen Pharmaceuticals, Inc.

Cempra, Inc.

Daewoong Pharmaceutical Co., Ltd.

Eisai Co., Ltd.

Ironwood Pharmaceuticals, Inc.

Johnson & Johnson

Ono Pharmaceutical Co., Ltd.

RaQualia Pharma Inc.

Rottapharm SpA

Shire Plc

Sucampo Pharmaceuticals, Inc.

Vecta Ltd.

Wockhardt Limited

Yuhan Corporation

Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutic Products under Development, Key Players in Reflux Esophagitis (Gastroesophageal Reflux Disease) Therapeutics, Reflux Esophagitis (Gastroesophageal Reflux Disease) Pipeline Overview, Reflux Esophagitis (Gastroesophageal Reflux Disease) Pipeline, Reflux Esophagitis (Gastroesophageal Reflux Disease) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com